The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
1 Director, Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
In this issue of Hepatology, Patel and 23 co-authors from Canada, the United States, New Zealand and Hong Kong report the results of a 24-week, phase 2, randomized, placebo-controlled trial of cilofexor in 140 adults with nonalcoholic steatohepatitis (NASH).1 Like obeticholic acid, cilofexor is a potent agonist of the farnesoid X receptor (FXR: a "-fexor") the major bile acid sensing nuclear receptor found in liver and intestine.2 Unlike obeticholic acid, cilofexor is a non-steroidal small molecule, belonging to the "hammerhead" class of compounds that bind to and activate FXR